Details of the Drug

General Information of Drug (ID: DM5UXAB)

Drug Name
SAR442085
Indication
Disease Entry ICD 11 Status REF
Plasma cell myeloma 2A83.1 Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D5VE7C

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclic ADP-ribose hydrolase 1 (CD38) TTPURFN CD38_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Plasma cell myeloma
ICD Disease Classification 2A83.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cyclic ADP-ribose hydrolase 1 (CD38) DTT CD38 8.33E-02 0.22 0.69
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04000282) First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Sanofi.